News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The ACTG Immunizes First Subject in Clinical Trial of Profectus BioSciences, Inc.'s Therapeutic HIV DNA Vaccine


5/25/2011 11:15:12 AM

Profectus BioSciences, Inc., a leader in the development of therapeutic vaccines against chronic infectious diseases and cancers, announced today that the AIDS Clinical Trials Group (ACTG) has immunized the first subject in a U.S. phase 1 clinical trial of Profectus’ multi-antigen HIV plasmid DNA (MAG-pDNA) vaccine administered with various doses of GENEVAX™ interleukin-12 (IL-12) pDNA adjuvant and delivered using the electroporation (EP) based TriGrid™delivery system (TriGrid) developed by Ichor Medical Systems. This multi-center study is being sponsored by the National Institutes of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The study is being conducted by the NIAID-funded ACTG under a protocol designated A5281.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES